International Biotechnology Trust’s Nektar Therapeutics NKTR Stock Holding History

International Biotechnology Trust’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,467	Closed	-$905K	–	78
2021 Q4	$905K	Hold	4,467	–	–	0.2%	58
2021 Q3	$1.2M	Hold	4,467	–	–	0.29%	52
2021 Q2	$1.15M	Hold	4,467	–	–	0.3%	50
2021 Q1	$1.34M	Hold	4,467	–	–	0.35%	43
2020 Q4	$1.14M	Hold	4,467	–	–	0.31%	41
2020 Q3	$1.11M	Hold	4,467	–	–	0.36%	40
2020 Q2	$1.5M	Hold	4,467	–	–	0.5%	33
2020 Q1	$1.19M	Sell	4,467 -4,866	-52%	-$1.51M	0.54%	32
2019 Q4	$3.02M	Buy	9,333 +5,333	+133%	+$1.55M	1.09%	24
2019 Q3	$1.09M	Hold	4,000	–	–	0.51%	39
2019 Q2	$2.13M	Hold	4,000	–	–	0.79%	34
2019 Q1	$2.02M	Hold	4,000	–	–	0.74%	39
2018 Q4	$1.55M	Buy	+4,000	New	+$2.41M	0.96%	27
2018 Q1	–	Sell	-14,067	Closed	-$12.6M	–	66
2017 Q4	$12.6M	Buy	+14,067	New	+$8.32M	4.44%	4
2017 Q2	–	Sell	-4,000	Closed	-$1.41M	–	65
2017 Q1	$1.41M	Hold	4,000	–	–	0.54%	38
2016 Q4	$736K	Buy	+4,000	New	+$813K	0.33%	42

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

International Biotechnology Trust's NKTR Position: Q1 2022 in Review

International Biotechnology Trust sold out of Nektar Therapeutics (NKTR) in Q1 2022, closing a stake of 4,467 shares — an estimated $905K sold.

International Biotechnology Trust first reported a position in NKTR in Q4 2016 and held it in 16 quarters. The position peaked at $12.6M in Q4 2017. 239 funds tracked by Wall St. Rank hold NKTR as of Q1 2022.

International Biotechnology Trust reported no remaining Nektar Therapeutics position as of Q1 2022 after selling out during the quarter.
International Biotechnology Trust sold 4,467 Nektar Therapeutics shares in Q1 2022, an estimated $905K.
International Biotechnology Trust first reported a position in Nektar Therapeutics in Q4 2016 and held it in 16 quarters.
International Biotechnology Trust's Nektar Therapeutics position peaked at $12.6M in Q4 2017.
239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2022.

Based on International Biotechnology Trust's 13F filing for Q1 2022, filed 20 May 2022.